NCT03756883View on ClinicalTrials.gov

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

999

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

October 26, 2019

Study Completion Date

November 10, 2019

Conditions
Asthma
Interventions
DRUG

Fluticasone Propionate and Salmeterol Inhalation Powder

100/50 mcg per actuation

DRUG

Fluticasone Propionate and Salmeterol Inhalation Powder

100/50 mcg per actuation

DRUG

Placebo Inhalation Powder

No active content

Trial Locations (1)

33014

Study Site 101, Miami Lakes

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

Actavis Inc.

INDUSTRY

NCT03756883 - Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma | Biotech Hunter | Biotech Hunter